Amrubicin
Sponsors
Celgene Corporation, Celgene, Lawrence Einhorn, SCRI Development Innovations, LLC, University of Utah
Conditions
Advanced Solid TumorsBladder CancerExtensive-Stage Small Cell Lung CancerLung CancerMetastatic Breast CancerMultiple MyelomaSmall Cell Lung CancerSmall Cell Lung Cancer (SCLC)
Phase 1
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
CompletedNCT00890955
Start: 2009-03-31End: 2010-07-31Updated: 2015-12-23
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
CompletedNCT00915083
Start: 2009-06-01End: 2011-05-01Updated: 2019-11-01
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
CompletedNCT01033032
Start: 2009-12-31End: 2014-10-31Updated: 2022-05-03
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
CompletedNCT01355705
Start: 2011-08-31End: 2017-07-31Updated: 2018-09-18
Phase 2
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
CompletedNCT00319969
Start: 2006-04-30End: 2009-01-31Updated: 2009-09-30
Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy
CompletedNCT00375193
Start: 2006-11-01End: 2009-03-01Updated: 2019-10-24
Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer
WithdrawnNCT00380835
End: 2007-12-31Target: 66Updated: 2008-09-23
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
CompletedNCT00388960
Start: 2006-11-01End: 2010-12-01Updated: 2019-11-19
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
CompletedNCT01076504
Start: 2009-12-31End: 2015-03-31Updated: 2016-05-05
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma
CompletedNCT01259375
Start: 2011-09-30End: 2016-02-29Updated: 2017-04-17
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
TerminatedNCT01331824
Start: 2011-02-28End: 2015-07-31Updated: 2018-04-23
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
CompletedNCT01364727
Start: 2011-06-30End: 2018-12-31Updated: 2019-04-16
Phase 3
AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
CompletedNCT00547651
Start: 2007-09-01End: 2011-05-01Updated: 2019-11-06
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
CompletedNCT02481830
Start: 2015-09-14End: 2022-08-30Updated: 2023-07-27
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Active, not recruitingNCT05740566
Start: 2023-05-31End: 2028-03-26Updated: 2026-01-05
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RecruitingNCT06203210
Start: 2024-05-21End: 2029-02-22Target: 540Updated: 2026-03-02
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Not yet recruitingNCT07365241
Start: 2026-04-14End: 2030-09-01Target: 531Updated: 2026-01-26